医学
达拉图穆马
来那度胺
地塞米松
多发性骨髓瘤
内科学
硼替佐米
肿瘤科
作者
Pieter Sonneveld,Meletios Α. Dimopoulos,Mario Boccadoro,Hang Quach,P. Joy Ho,Meral Beksaç,Cyrille Hulin,Elisabetta Antonioli,Xavier Leleu,Silvia Mangiacavalli,Aurore Perrot,Michèle Cavo,Angelo Belotti,Annemiek Broijl,Francesca Gay,Roberto Mina,Inger S. Nijhof,Niels W.C.J. van de Donk,Eirini Katodritou,Fredrik Schjesvold
标识
DOI：10.1056/nejmoa2312054
摘要
The addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy conferred a significant benefit with respect to progression-free survival among transplantation-eligible patients with newly diagnosed multiple myeloma. (Funded by the European Myeloma Network in collaboration with Janssen Research and Development; PERSEUS ClinicalTrials.gov number, NCT03710603; EudraCT number, 2018-002992-16.).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
Kao
77
云天河
OK
GingerF
lizhi
奔跑
归零者
踏实一德
My_magnum_opus
张欢馨
清平道人
DrHHB
天晴
谢大喵
ming2026
lobster
修仙中
dde
石宇奇
皖公网安备34019202002308
